| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $16.6M | — | +113.6% |
| SG&A Expense | $5.9M | — | +117.2% |
| Operating Income | -$22.5M | — | -114.6% |
| Net Income | -$21.6M | — | -131.9% |
| EPS (Basic) | -$0.99 | — | -39.4% |
| EPS (Diluted) | -$0.99 | — | -39.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $62.4M | +32.7% | +135.6% |
| Short-term Investments | $28.8M | -54.3% | -76.9% |
| Current Assets | $93.6M | -16.4% | -39.5% |
| Total Assets | $98.6M | -15.9% | -37.2% |
| Current Liabilities | $11.6M | +10.0% | +94.2% |
| Total Liabilities | $11.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.9M | — | -65.7% |
| Investing Cash Flow | $34.3M | — | +130.4% |
| Financing Cash Flow | $4K | — | -100.0% |
| +83.1% |
| Stockholders' Equity | $87.0M | -18.4% | -42.3% |